Product news

Share this article:
Nycomed said the FDA has approved Alvesco (ciclesonide) inhalation aerosol in the US for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older. Alvesco is an inhaled corticosteroid with novel release and distribution properties.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters